Company Cosmo Pharmaceuticals S.p.A Swiss Exchange
Equities
IT0004167463
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- CHF | - |
|
Business Summary
Sales per Business
CHF in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Own Products
52.0
%
| 43 | 60.6 % | 53 | 52.0 % | +25.05% |
Licence Fees, Up-front Fees and Milestones
23.8
%
| 6 | 8.5 % | 24 | 23.8 % | +310.51% |
Generic Products, Specialty Drugs and Related Services
12.9
%
| 14 | 19.4 % | 13 | 12.9 % | -3.41% |
Royalties
9.7
%
| 6 | 8.6 % | 10 | 9.7 % | +63.17% |
Other
1.6
%
| 2 | 2.9 % | 2 | 1.6 % | -17.40% |
Sales per region
CHF in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Italy
100.0
%
| 70 | 100.0 % | 102 | 100.0 % | +45.72% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 16-05-31 |
Chairman | 61 | 05-12-31 | |
Chief Tech/Sci/R&D Officer | 54 | - | |
Luigi Longo
CTO | Chief Tech/Sci/R&D Officer | 45 | 05-05-31 |
Davide Malavasi
CTO | Chief Tech/Sci/R&D Officer | 51 | 11-08-31 |
Marco Lecchi
COO | Chief Operating Officer | 60 | 00-12-31 |
Hazel Winchester
IRC | Investor Relations Contact | 53 | 22-01-09 |
Nhan Ngo Dinh
PRN | Corporate Officer/Principal | 45 | - |
Biagio Viganò
HRO | Human Resources Officer | 50 | - |
Diana Harbort
PRN | Corporate Officer/Principal | 57 | 21-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 96-12-31 | |
Director/Board Member | 69 | 12-03-31 | |
Chairman | 61 | 05-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 17,543,522 | 7,781,904 ( 44.36 %) | 1,490,681 ( 8.497 %) | 44.36 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
1,283,390 | 7.32% | 100,719,408 $ |
Company contact information
Cosmo Pharmaceuticals NV
Riverside II Sir John Rogerson's Quay
2, Dublin
+353 1 817 0370
http://www.cosmopharma.com![address Cosmo Pharmaceuticals S.p.A](https://cdn.zonebourse.com/static/address/236039.png)
Group companies
Name | Category and Sector |
---|---|
Granell Strategic Investment Fund Ltd.
|
Investment Managers
|
Cosmo Technologies Ltd.
![]() Cosmo Technologies Ltd. Pharmaceuticals: MajorHealth Technology Part of Cosmo Pharmaceuticals NV, Cosmo Technologies Ltd. is an Irish pharmaceutical company that manufactures and distributes pharmaceutical products. The company is based in Dublin, Ireland. Cosmo Technologies was acquired by Salix Pharmaceuticals Ltd. from Cosmo Pharmaceuticals SA. |
Pharmaceuticals: Major
|
Pharmaceuticals: Major
|
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
+55.76% | 819B | |
-6.83% | 351B | |
+16.26% | 329B | |
+10.27% | 298B | |
+16.57% | 242B | |
+2.04% | 225B | |
+13.31% | 217B | |
+8.58% | 168B | |
-2.94% | 158B |
- Stock Market
- Equities
- COPN Stock
- Stock
- Company Cosmo Pharmaceuticals S.p.A